Opinion|Videos|July 12, 2024
Emerging Data from ASCO 2024 in HER2-low: DESTINY-Breast06
Dr Gadi leads a discussion on recent data on the treatment of HER2-low tumors, including ASCO updates on the DESTINY-Breast06 trial.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Can you please offer an overview of the primary results from the DESTINY-PanTumor02 trial (Meric-Bernstam_J Clin Oncol_2024), specifically in regard to each of the following:
- cervical
- ovarian cancers
- endometrial
- STATICE trial results (Nishikawa J Clin Oncol 2023)
- What is the potential for DB-1303 in endometrial cancer (Moore_J Clin Oncol_2023)
- Where in the treatment sequencing do you expect HER2-direct ADCs to fit?
Newsletter
Stay up to date on the most recent and practice-changing oncology data
SubscribeAdvertisement
Related to this article
First-line IO-based combination regimens were increasingly used and associated with longer observed survival in advanced renal cell carcinoma.
Tenumomeran/raplemomeran plus pembrolizumab missed the PFS end point in HPV16-positive HNSCC.
Matthew P. Goetz, MD, explores first-line treatment selection, emerging targeted therapies, and unmet sequencing needs in metastatic breast cancer.
AI-assisted scoping review of code sharing in clinical prediction model research
Omar Castaneda Puglianini, MD, discusses earlier CAR T-cell therapy use, sequencing with bispecific antibodies, and access barriers in multiple myeloma.
Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ESMO 2026.
The FDA granted fast track designation to opamtistomig for first-line treatment of advanced or metastatic biliary tract cancer.
Roswell Park Comprehensive Cancer Center has earned national recognition in 2026 from the American Medical Association as a Joy in Medicine organization.
Advertisement
Advertisement